- Current report filing (8-K)
July 24 2012 - 8:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 24, 2012
MAP PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified
in its Charter)
Delaware
|
|
001-33719
|
|
20-0507047
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
2400 Bayshore Parkway, Suite
200,
Mountain View, CA
|
|
94043
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (650) 386-3100
(Former Name or Former Address, if Changed
Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02
|
Results of Operations and Financial Condition
|
On July 24, 2012, MAP Pharmaceuticals, Inc.
(“MAP”) issued a press release announcing its financial results for its second quarter ended June 30, 2012. A copy
of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 of
this Current Report on Form 8-K and the information contained in Exhibit 99.1 shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of that Section. The information in this Item 2.02 of this Current Report on Form 8-K and the press release
referenced herein is not incorporated by reference into any filings of MAP under the Securities Act of 1933, as amended, or the
Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation
language in the filing, unless explicitly incorporated by specific reference into such filing.
Item 9.01
|
Financial Statements and Exhibits
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press Release of MAP Pharmaceuticals, Inc., dated July 24, 2012
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 24, 2012
|
MAP PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
|
/s/
Charlene A. Friedman
|
|
Name:
|
|
Charlene A. Friedman
|
|
Title:
|
|
Senior Vice President, General Counsel and Secretary
|
INDEX TO EXHIBITS FILED WITH
THE CURRENT REPORT ON FORM 8-K DATED
JULY 24, 2012
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Press Release of MAP Pharmaceuticals, Inc., dated Jul 24, 2012.
|
Map Pharmaceuticals, Inc. (MM) (NASDAQ:MAPP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Map Pharmaceuticals, Inc. (MM) (NASDAQ:MAPP)
Historical Stock Chart
From Jul 2023 to Jul 2024